Wells Fargo
SGMT icon

Wells Fargo’s Sagimet Biosciences SGMT Stock Holding History

Wells Fargo’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Buy
63,996
+54,722
+590% +$372K ﹤0.01% 4635
2026
Q1 		$48.5K Buy
9,274
+1,274
+16% +$7.1K ﹤0.01% 5465
2025
Q4 		$47.4K Buy
8,000
+1,000
+14% +$7.18K ﹤0.01% 5589
2025
Q3 		$48K Buy
7,000
+500
+8% +$4.05K ﹤0.01% 5559
2025
Q2 		$49.5K Sell
6,500
-11,000
-63% -$46.4K ﹤0.01% 5509
2025
Q1 		$57K Buy
17,500
+10,690
+157% +$44.8K ﹤0.01% 5356
2024
Q4 		$30.6K Buy
+6,810
New +$34.5K ﹤0.01% 5633
2024
Q2 		– Sell
-7,519
Closed -$40.8K – 7396
2024
Q1 		$40.8K Buy
7,519
+5,931
+373% +$42.6K ﹤0.01% 5340
2023
Q4 		$8.61K Buy
1,588
+373
+31% +$1.76K ﹤0.01% 5870
2023
Q3 		$10.7K Buy
+1,215
New +$16.2K ﹤0.01% 5792

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Wells Fargo's SGMT Position: Q2 2026 in Review

Wells Fargo increased its Sagimet Biosciences (SGMT) stake by 590% in Q2 2026, buying an estimated $372K and bringing the position to 63,996 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #4635.

Wells Fargo first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Wells Fargo held 63,996 shares of Sagimet Biosciences worth $495K as of Q2 2026.
  • Wells Fargo bought 54,722 Sagimet Biosciences shares in Q2 2026, an estimated $372K.
  • Sagimet Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4635 holding.
  • Wells Fargo first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.